GRAIL
Listed · Nasdaq · GRALNot ranked by UbackUback segment Healthtech › Medtech › In-vitro diagnostics
Multi-cancer early detection blood test (Galleri).
Market value on the ranking date
Market capUSD 7.1bn · Oct 2026
ListingNasdaq · GRAL
CountryUnited States
Published figures
GRAIL and its private challengers · In-vitro diagnostics
Non-listed in-vitro diagnostics companies ranked by Uback, with GRAIL and the other listed pure players shown in grey at their market value on the ranking date (28 Oct 2026). Listed companies are never ranked.
| # | Company | Valuation | |
|---|---|---|---|
| — | NateraUnited States · Listed · Nasdaq · NTRA | USD 28bnMarket cap · Mar 2026 | |
| — | Guardant HealthUnited States · Listed · Nasdaq · GH | USD 12bnMarket cap · Mar 2026 | |
| — | GRAILUnited States · Listed · Nasdaq · GRAL | USD 7.1bnMarket cap · Oct 2026 | |
| 1 | Function HealthUnited States | ≈ USD 2.5bnUnicorn · AI estimate | Back |
| — | FreenomeUnited States · Listed · Nasdaq · FRNM | USD 1.37bnMarket cap · Oct 2026 | |
| 2 | Delfi DiagnosticsUnited States | ≈ USD 1.2bnUnicorn · AI estimate | Back |
| 3 | EverlywellUnited States | ≈ USD 900MHundreds of M$ · AI estimate | Back |
| 4 | LetsGetCheckedIreland | ≈ USD 770MHundreds of M$ · AI estimate | Back |
| 5 | Harbinger HealthUnited States | ≈ USD 520MHundreds of M$ · AI estimate | Back |
| 6 | KariusUnited States | ≈ USD 520MHundreds of M$ · AI estimate | Back |
| 7 | Truvian HealthUnited States | ≈ USD 380MHundreds of M$ · AI estimate | Back |
| 8 | MirvieUnited States | ≈ USD 310MHundreds of M$ · AI estimate | Back |
| 9 | InflammatixUnited States | ≈ USD 290MHundreds of M$ · AI estimate | Back |
| 10 | deepullSpain | ≈ USD 290MHundreds of M$ · AI estimate | Back |
| 11 | Visby MedicalUnited States | ≈ USD 280MHundreds of M$ · AI estimate | Back |
| 12 | HealthiansIndia | ≈ USD 280MHundreds of M$ · AI estimate | Back |
| 13 | Orange HealthIndia | ≈ USD 260MHundreds of M$ · AI estimate | Back |
| 14 | Redcliffe LabsIndia | ≈ USD 220MHundreds of M$ · AI estimate | Back |
| 15 | CraifJapan | ≈ USD 170MHundreds of M$ · AI estimate | Back |
| 16 | AbionicSwitzerland | ≈ USD 110MHundreds of M$ · AI estimate | Back |
| 17 | SpotitEarlyIsrael | ≈ USD 100MHundreds of M$ · AI estimate | Back |
| 18 | PrenosisUnited States | ≈ USD 100MHundreds of M$ · AI estimate | Back |
| 19 | LucisFrance | ≈ USD 100MHundreds of M$ · AI estimate | Back |
| 20 | LucenceSingapore | ≈ USD 100MHundreds of M$ · AI estimate | Back |
| 21 | Day Zero DiagnosticsUnited States | ≈ USD 83MTens of M$ · AI estimate | Back |
| 22 | TethisItaly | ≈ USD 80MTens of M$ · AI estimate | Back |
| 23 | Ilara HealthKenya | ≈ USD 19MTens of M$ · AI estimate | Back |
| 24 | OncoliqArgentina | ≈ USD 15MTens of M$ · AI estimate | Back |
| 25 | RedbirdGhana | ≈ USD 7.7MMillions $ · AI estimate | Back |
Declare an interest in In-vitro diagnostics Full In-vitro diagnostics ranking →
Figures as published by the company and market data, at the date shown.
Uback is a content publisher. It ranks non-listed companies only and gives no opinion on listed companies: the figures above are facts as published, at the date shown, never a recommendation. No intention can be declared on a listed company. Method